Faiz Mumtaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Faiz Mumtaz has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Maxine Gia Binh Tran
Division of Surgery and Interventional Sciences, University College London, London, UK
7 shared publications Axel Bex
Specialist Centre for Kidney Cancer Royal Free Hospital NHS Trust London UK
4 shared publications- Prasad Patki
Department of Urology The Royal Free London NHS Foundation Trust London UK
4 shared publications Ravi Barod
Department of Urology The Royal Free London NHS Foundation Trust London UK
4 shared publications- Teele Kuusk
Department of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
4 shared publications - Yasmin Abu-Ghanem
Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London SE1 7EH, UK
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1133-1141
Towards sustainable multidisciplinary renal cancer tumour boards: redesigning the referral pathway
Objectives: To develop and evaluate a complexity‐stratified referral pathway aimed at improving the sustainability, efficiency and resource utilisation of specialist multidisciplinary team (SMDT) meetings within a high‐volume tertiary renal cancer service. Patients and Methods: We performed a retrospective cohort study of benign and malignant renal cancer cases discussed at SMDT meetings between January and December 2023 at the Royal Free Specialist Centre for Kidney Cancer. Patient demographics, tumour characteristics, SMDT discussions and management outcomes of patients were analysed to identify protocolised lower complexity cases suitable for alternative MDT pathways. Based on these findings, dedicated Standard of Care (SoC) and Benign MDTs were developed and implemented to manage lower complexity renal cases outside the main SMDT. The impact of the revised referral structure on SMDT workload, discussion efficiency and specialist resource utilisation was subsequently evaluated. Results: In 2023, 2228 patients with benign and malignant renal pathology underwent 4154 SMDT discussions. Most patients (96.3%) required under seven discussions. Patients aged >70 years with renal masses <2 cm frequently underwent repeated SMDT review, despite surveillance or conservative management representing the most common management recommendation. Bosniak I–II cysts were predominantly discharged, whilst Bosniak IIF cysts were mainly managed with surveillance. Following implementation of the revised referral structure incorporating SoC and Benign MDTs, cases discussed at the main SMDT decreased from a mean of 83 to 63 patients with cancer per week, whilst discussion time per patient increased by 30.8%. The revised pathway also reduced the requirement for full SMDT attendance for protocolised cases. Conclusion: Complexity‐stratified MDT referral structure improved efficiency and sustainability by diverting lower complexity protocolised cases to dedicated Benign and SoC MDTs. This enabled the main SMDT to prioritise clinically complex decision making and optimise utilisation of specialist multidisciplinary expertise.
- 1 October 2026
- Published by Wiley in BJU International
- Vol. 138 (6) , 1133-1141
Open AccessTowards sustainable multidisciplinary renal cancer tumour boards: redesigning the referral pathway
Objectives: To develop and evaluate a complexity‐stratified referral pathway aimed at improving the sustainability, efficiency and resource utilisation of specialist multidisciplinary team (SMDT) meetings within a high‐volume tertiary renal cancer service. Patients and Methods: We performed a retrospective cohort study of benign and malignant renal cancer cases discussed at SMDT meetings between January and December 2023 at the Royal Free Specialist Centre for Kidney Cancer. Patient demographics, tumour characteristics, SMDT discussions and management outcomes of patients were analysed to identify protocolised lower complexity cases suitable for alternative MDT pathways. Based on these findings, dedicated Standard of Care (SoC) and Benign MDTs were developed and implemented to manage lower complexity renal cases outside the main SMDT. The impact of the revised referral structure on SMDT workload, discussion efficiency and specialist resource utilisation was subsequently evaluated. Results: In 2023, 2228 patients with benign and malignant renal pathology underwent 4154 SMDT discussions. Most patients (96.3%) required under seven discussions. Patients aged >70 years with renal masses <2 cm frequently underwent repeated SMDT review, despite surveillance or conservative management representing the most common management recommendation. Bosniak I–II cysts were predominantly discharged, whilst Bosniak IIF cysts were mainly managed with surveillance. Following implementation of the revised referral structure incorporating SoC and Benign MDTs, cases discussed at the main SMDT decreased from a mean of 83 to 63 patients with cancer per week, whilst discussion time per patient increased by 30.8%. The revised pathway also reduced the requirement for full SMDT attendance for protocolised cases. Conclusion: Complexity‐stratified MDT referral structure improved efficiency and sustainability by diverting lower complexity protocolised cases to dedicated Benign and SoC MDTs. This enabled the main SMDT to prioritise clinically complex decision making and optimise utilisation of specialist multidisciplinary expertise.
- Open Access
- 22 September 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (9) , e70068
Staging CT chest for cT1a renal masses: Does it change management?
Objectives: Baseline staging investigations for renal masses invariably include a CT of the chest. However, EAU guidelines have given a weak recommendation that CT chest can be omitted in incidental T1a tumours (≤4 cm) without systemic symptoms, due to the low incidence of pulmonary metastases. This study aimed to assess if a baseline staging CT chest has been clinically useful in a cohort with T1a renal tumours.Methods: Consecutive patients with solid and cystic cT1a renal tumours were prospectively screened for eligibility to the NEST study (ISRCTN 18156881) at a single tertiary referral centre multidisciplinary team meeting (MDT). Four hundred consecutive eligible patients between 28/05/2019 and 13/01/2021 were included in this study. Electronic records were reviewed retrospectively for follow‐up data. Seventeen patients with incomplete follow‐up data were excluded.Results: Of 383 included patients (63% male, median age 65 years, median tumour diameter 2.4 cm), 264 (69%) had a baseline CT chest as part of their clinical staging investigations. No thoracic renal metastases were diagnosed. Abnormalities were reported in 37/264 cases (14%), including indeterminate lung lesions in 32 patients that were deemed benign on further investigations, three synchronous primary lung tumours, one pre‐existing mesothelioma and one pleural effusion related to known renal failure.Conclusion: CT chest is of limited value in clinical staging investigations for cT1a renal tumours and has a negligible impact on subsequent renal tumour management. Rather, it triggered further investigations and follow‐up for 14% of incidentalomas and ultimately detected concurrent incidental primary lung tumours in 1% of patients.
- 22 September 2025
- Published by Wiley in BJUI Compass
- Vol. 6 (9) , e70068
Open AccessStaging CT chest for cT1a renal masses: Does it change management?
Objectives: Baseline staging investigations for renal masses invariably include a CT of the chest. However, EAU guidelines have given a weak recommendation that CT chest can be omitted in incidental T1a tumours (≤4 cm) without systemic symptoms, due to the low incidence of pulmonary metastases. This study aimed to assess if a baseline staging CT chest has been clinically useful in a cohort with T1a renal tumours.Methods: Consecutive patients with solid and cystic cT1a renal tumours were prospectively screened for eligibility to the NEST study (ISRCTN 18156881) at a single tertiary referral centre multidisciplinary team meeting (MDT). Four hundred consecutive eligible patients between 28/05/2019 and 13/01/2021 were included in this study. Electronic records were reviewed retrospectively for follow‐up data. Seventeen patients with incomplete follow‐up data were excluded.Results: Of 383 included patients (63% male, median age 65 years, median tumour diameter 2.4 cm), 264 (69%) had a baseline CT chest as part of their clinical staging investigations. No thoracic renal metastases were diagnosed. Abnormalities were reported in 37/264 cases (14%), including indeterminate lung lesions in 32 patients that were deemed benign on further investigations, three synchronous primary lung tumours, one pre‐existing mesothelioma and one pleural effusion related to known renal failure.Conclusion: CT chest is of limited value in clinical staging investigations for cT1a renal tumours and has a negligible impact on subsequent renal tumour management. Rather, it triggered further investigations and follow‐up for 14% of incidentalomas and ultimately detected concurrent incidental primary lung tumours in 1% of patients.
- Open Access
- 7 July 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 590-601
Natural history of treated and untreated renal oncocytoma: a systematic review and meta‐analysis
Introduction: Current guidelines recommend active surveillance, surgery, and ablation all as acceptable management strategies for renal oncocytoma, but there is growing concern about overtreatment. Our aim was to report the natural history of treated and untreated renal oncocytoma to inform clinical guidelines and shared decision‐making. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA). We systematically reviewed MEDLINE, EMBASE, CENTRAL and Clinicaltrials.gov from inception to 18 August 2023. Studies that reported outcomes during follow‐up for adult patients with treated and untreated histologically confirmed renal oncocytoma were included. The Joanna Briggs Institute tool was used to assess risk of bias for included studies. We present a narrative review and meta‐analysis. Results: There are no reports of distant metastases or disease‐related death for oncocytoma on active surveillance. Most oncocytomas on surveillance show limited growth (2 /year). A significant minority (14%) transition to active treatment, most often for tumour growth. Concordance between biopsy and surgical pathology was high (89%). Metastatic oncocytoma and disease‐related death after treatment was negligible, and exclusively in reports using historic diagnostic criteria defined prior to the World Health Organisation 1998 classification, and therefore likely including eosinophilic renal cell carcinomas. Conclusion: Active surveillance of oncocytoma is oncologically safe and allows patients to avoid the risk of morbidity and mortality with treatment. Imaging surveillance after active treatment can be safely omitted. The literature would benefit from prospective cohort studies of oncocytomas on surveillance, reporting surveillance protocols, and clinical outcomes including reasons for transition to active treatment.
- 7 July 2025
- Published by Wiley in BJU International
- Vol. 136 (4) , 590-601
Open AccessNatural history of treated and untreated renal oncocytoma: a systematic review and meta‐analysis
Introduction: Current guidelines recommend active surveillance, surgery, and ablation all as acceptable management strategies for renal oncocytoma, but there is growing concern about overtreatment. Our aim was to report the natural history of treated and untreated renal oncocytoma to inform clinical guidelines and shared decision‐making. Methods: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐analyses (PRISMA). We systematically reviewed MEDLINE, EMBASE, CENTRAL and Clinicaltrials.gov from inception to 18 August 2023. Studies that reported outcomes during follow‐up for adult patients with treated and untreated histologically confirmed renal oncocytoma were included. The Joanna Briggs Institute tool was used to assess risk of bias for included studies. We present a narrative review and meta‐analysis. Results: There are no reports of distant metastases or disease‐related death for oncocytoma on active surveillance. Most oncocytomas on surveillance show limited growth (2 /year). A significant minority (14%) transition to active treatment, most often for tumour growth. Concordance between biopsy and surgical pathology was high (89%). Metastatic oncocytoma and disease‐related death after treatment was negligible, and exclusively in reports using historic diagnostic criteria defined prior to the World Health Organisation 1998 classification, and therefore likely including eosinophilic renal cell carcinomas. Conclusion: Active surveillance of oncocytoma is oncologically safe and allows patients to avoid the risk of morbidity and mortality with treatment. Imaging surveillance after active treatment can be safely omitted. The literature would benefit from prospective cohort studies of oncocytomas on surveillance, reporting surveillance protocols, and clinical outcomes including reasons for transition to active treatment.
- 2 April 2025
- Published by Wiley in BJU International
- Vol. 135 (6) , 918-920
Caval thrombectomy a urological leap into the unknown – a call for action
- 2 April 2025
- Published by Wiley in BJU International
- Vol. 135 (6) , 918-920
Caval thrombectomy a urological leap into the unknown – a call for action
- Open Access
Prevalence and risk factors of persistent cough in patients diagnosed with renal cell carcinoma: a systematic review and meta-analysis
Objectives: Cough occurring in patients with renal cell carcinoma (RCC) was first described in 1935 and is a frequently discussed symptom on patient forums. We aimed to systematically review the available evidence to explore the prevalence and risk factors for persistent cough in patients diagnosed with RCC to establish whether cough could be a presenting symptom of RCC. Design: This epidemiological systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 2020. Data sources: Medline, Embase, Science Citation Index, The Cochrane Library, ClinicalTrials.gov and the WHO trials register were searched without language restrictions until 1 June 2023. Eligibility criteria for selecting studies: We included articles of all study designs reporting cough in patients (18 years or older) with RCC attributed to the disease itself or to treatment. Data extraction and synthesis: Data from included articles was extracted using a preprepared and piloted form, and quality assessment was conducted independently by two authors. The risk of bias was assessed in studies other than case reports or case series using the critical appraisal instrument for studies reporting prevalence data. Narrative techniques were used for data analysis and, where appropriate, meta-analysis using a fixed-effects model was performed. Results: Of 509 studies screened, 105 full-text articles were assessed, with 46 papers subsequently excluded, resulting in 59 analysed in depth. There were 105 patients with RCC reported as having a cough due to the disease itself within 30 case reports and 8 case series. When present, most coughs were described as persistent and dry in nature. The cause of cough was attributed to various aetiologies including pulmonary and endobronchial metastasis and paraneoplastic syndromes. Studies reporting patients with RCC developing a cough because of systemic treatment were heterogeneous. Two studies with 238 patients on temsirolimus and 230 on interferon-α (IFN-α) were suitable for meta-analysis using a fixed-effects model. Patients on temsirolimus were more likely to develop a cough than those on IFN-α (OR 1.95 with a 95% CI of 1.05 to 3.63, overall effect Z=2.12 (p=0.03), I 2 =0%). Conclusion: Cough can occur in patients with RCC, as part of the disease pathogenesis, as an adverse effect of systemic treatment or due to unrelated causes such as pre-existing conditions (eg, asthma). Further research is required to determine the true prevalence and cause and to assess whether cough could be a presenting symptom for RCC. PROSPERO registration number: CRD42022302962.
Open AccessPrevalence and risk factors of persistent cough in patients diagnosed with renal cell carcinoma: a systematic review and meta-analysis
Objectives: Cough occurring in patients with renal cell carcinoma (RCC) was first described in 1935 and is a frequently discussed symptom on patient forums. We aimed to systematically review the available evidence to explore the prevalence and risk factors for persistent cough in patients diagnosed with RCC to establish whether cough could be a presenting symptom of RCC. Design: This epidemiological systematic review used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement 2020. Data sources: Medline, Embase, Science Citation Index, The Cochrane Library, ClinicalTrials.gov and the WHO trials register were searched without language restrictions until 1 June 2023. Eligibility criteria for selecting studies: We included articles of all study designs reporting cough in patients (18 years or older) with RCC attributed to the disease itself or to treatment. Data extraction and synthesis: Data from included articles was extracted using a preprepared and piloted form, and quality assessment was conducted independently by two authors. The risk of bias was assessed in studies other than case reports or case series using the critical appraisal instrument for studies reporting prevalence data. Narrative techniques were used for data analysis and, where appropriate, meta-analysis using a fixed-effects model was performed. Results: Of 509 studies screened, 105 full-text articles were assessed, with 46 papers subsequently excluded, resulting in 59 analysed in depth. There were 105 patients with RCC reported as having a cough due to the disease itself within 30 case reports and 8 case series. When present, most coughs were described as persistent and dry in nature. The cause of cough was attributed to various aetiologies including pulmonary and endobronchial metastasis and paraneoplastic syndromes. Studies reporting patients with RCC developing a cough because of systemic treatment were heterogeneous. Two studies with 238 patients on temsirolimus and 230 on interferon-α (IFN-α) were suitable for meta-analysis using a fixed-effects model. Patients on temsirolimus were more likely to develop a cough than those on IFN-α (OR 1.95 with a 95% CI of 1.05 to 3.63, overall effect Z=2.12 (p=0.03), I 2 =0%). Conclusion: Cough can occur in patients with RCC, as part of the disease pathogenesis, as an adverse effect of systemic treatment or due to unrelated causes such as pre-existing conditions (eg, asthma). Further research is required to determine the true prevalence and cause and to assess whether cough could be a presenting symptom for RCC. PROSPERO registration number: CRD42022302962.
- Open Access
Protocol for a mixed-method study to assess chronic cough in patients with renal cell carcinoma: the prevalence, impact on quality of life, trigger and potential clinical application of chronic cough as an early screening tool in patients with kidney cancer
Introduction Cough as a symptom of renal cell carcinoma (RCC) was first described by Creevy in 1935, and despite one (unpublished) study suggesting it may affect 31% of these patients, as well as cough being discussed in forums for patients with kidney cancer, few clinicians are aware of this association. The cough has been described as unusual in nature, resolving rapidly after treatment with nephrectomy/embolisation but returning if the tumour recurs. Methods and analysis A prospective study using a questionnaire will identify the prevalence of cough in patients with suspected or confirmed RCC attending the Specialist Centre for Kidney Cancer (London, UK). A longitudinal study in a representative sample of these patients, using EQ-5D-5L and Leicester Cough Questionnaires, together with the use of semi-structured interviews with patients, will identify the impact of cough in addition to having a diagnosis of suspected or confirmed RCC on quality of life. To investigate cough mechanisms, a pilot study using cough hypersensitivity testing will be performed on patients with RCC, with and without a cough. Clinical samples (urine, blood, phlegm and breath condensate) from patients with RCC, with and without a cough, will be collected and analysed for the presence of substances known to trigger or enhance cough and compared with the results obtained from healthy volunteers. Ethics and dissemination Ethical approval has been granted (UK HR REC 22/PR/0791 dated 25/08/2022). Study outputs will be presented and published nationally and internationally at relevant conferences. This study will establish the prevalence of cough in patients with suspected or confirmed kidney cancer and support the education of clinicians to consider this diagnosis in patients with chronic cough (eg, recommending protocols to include both kidneys when investigating respiratory symptoms with chest CT scans). If substances known to trigger or enhance cough are identified and elevated in clinical samples, this research could offer potential targets for treatment for this distressing symptom. Trial registration number NIHR CRN portfolio CPMS ID:53 372.
Open AccessProtocol for a mixed-method study to assess chronic cough in patients with renal cell carcinoma: the prevalence, impact on quality of life, trigger and potential clinical application of chronic cough as an early screening tool in patients with kidney cancer
Introduction Cough as a symptom of renal cell carcinoma (RCC) was first described by Creevy in 1935, and despite one (unpublished) study suggesting it may affect 31% of these patients, as well as cough being discussed in forums for patients with kidney cancer, few clinicians are aware of this association. The cough has been described as unusual in nature, resolving rapidly after treatment with nephrectomy/embolisation but returning if the tumour recurs. Methods and analysis A prospective study using a questionnaire will identify the prevalence of cough in patients with suspected or confirmed RCC attending the Specialist Centre for Kidney Cancer (London, UK). A longitudinal study in a representative sample of these patients, using EQ-5D-5L and Leicester Cough Questionnaires, together with the use of semi-structured interviews with patients, will identify the impact of cough in addition to having a diagnosis of suspected or confirmed RCC on quality of life. To investigate cough mechanisms, a pilot study using cough hypersensitivity testing will be performed on patients with RCC, with and without a cough. Clinical samples (urine, blood, phlegm and breath condensate) from patients with RCC, with and without a cough, will be collected and analysed for the presence of substances known to trigger or enhance cough and compared with the results obtained from healthy volunteers. Ethics and dissemination Ethical approval has been granted (UK HR REC 22/PR/0791 dated 25/08/2022). Study outputs will be presented and published nationally and internationally at relevant conferences. This study will establish the prevalence of cough in patients with suspected or confirmed kidney cancer and support the education of clinicians to consider this diagnosis in patients with chronic cough (eg, recommending protocols to include both kidneys when investigating respiratory symptoms with chest CT scans). If substances known to trigger or enhance cough are identified and elevated in clinical samples, this research could offer potential targets for treatment for this distressing symptom. Trial registration number NIHR CRN portfolio CPMS ID:53 372.
- 27 July 2021
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 16 (3) , 611-619
Perioperative impact of body mass index on upper urinary tract and renal robot-assisted surgery: a single high-volume centre experience
To assess the impact of body mass index (BMI) on peri-operative outcomes of kidney and upper tract robot-assisted surgery. Medical audit of patients who underwent robot-assisted kidney and upper tract cancer surgery at a single institution between 2017 and 2019, categorized on BMI into obese patients with a BMI ≥ 30 kg/m2 and a control group with BMI < 25 kg/m2. Patient and tumour characteristics, surgery time, intraoperative blood loss, intraoperative adverse events (AE) according to the European Association of Urology Intraoperative Adverse Incidents Classification (EAUiaiC), conversion- to-open/radical rate as well as 30-day postoperative AE according to Clavien-Dindo (CD) and length of inpatient stay were analyzed. 366 patients were identified, 141 with a BMI < 25 (normal-weight) and 225 BMI ≥ 30 (obesity). There were no significant differences between the groups in terms of age, gender, comorbidities, tumour size, TNM stage and type of surgery. Obese patients had a higher estimated blood loss (198.05 ml), surgery time (171.75 min), intraoperative AE (all grades) (14.67%, 95% CI (0.10–0.19) as well as adherent perinephric fat (APF) (14.22%, 95% CI (0.09–0.19)) in contrast to the control group (86.85 ml, 148.29 min, 7.04% and 2.12%, respectively). Hospital stay, major intraoperative AE (≥ 3) and major postoperative AE (CD > 2) distributed equally between groups. Robotic kidney and upper tract surgery in obese patients showed an increase in surgery time and blood loss potentially related to APF. However, obesity was not associated with conversion to open surgery or radical nephrectomy in nephron-sparing procedures, length of stay, major intraoperative AE or postoperative complications.
- 27 July 2021
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 16 (3) , 611-619
Perioperative impact of body mass index on upper urinary tract and renal robot-assisted surgery: a single high-volume centre experience
To assess the impact of body mass index (BMI) on peri-operative outcomes of kidney and upper tract robot-assisted surgery. Medical audit of patients who underwent robot-assisted kidney and upper tract cancer surgery at a single institution between 2017 and 2019, categorized on BMI into obese patients with a BMI ≥ 30 kg/m2 and a control group with BMI < 25 kg/m2. Patient and tumour characteristics, surgery time, intraoperative blood loss, intraoperative adverse events (AE) according to the European Association of Urology Intraoperative Adverse Incidents Classification (EAUiaiC), conversion- to-open/radical rate as well as 30-day postoperative AE according to Clavien-Dindo (CD) and length of inpatient stay were analyzed. 366 patients were identified, 141 with a BMI < 25 (normal-weight) and 225 BMI ≥ 30 (obesity). There were no significant differences between the groups in terms of age, gender, comorbidities, tumour size, TNM stage and type of surgery. Obese patients had a higher estimated blood loss (198.05 ml), surgery time (171.75 min), intraoperative AE (all grades) (14.67%, 95% CI (0.10–0.19) as well as adherent perinephric fat (APF) (14.22%, 95% CI (0.09–0.19)) in contrast to the control group (86.85 ml, 148.29 min, 7.04% and 2.12%, respectively). Hospital stay, major intraoperative AE (≥ 3) and major postoperative AE (CD > 2) distributed equally between groups. Robotic kidney and upper tract surgery in obese patients showed an increase in surgery time and blood loss potentially related to APF. However, obesity was not associated with conversion to open surgery or radical nephrectomy in nephron-sparing procedures, length of stay, major intraoperative AE or postoperative complications.
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S244
Minimally Invasive Surgery (MIS) in simple nephrectomy – differences in perioperative outcomes based on infectious or noninfectious aetiology
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S244
Minimally Invasive Surgery (MIS) in simple nephrectomy – differences in perioperative outcomes based on infectious or noninfectious aetiology
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1108
High volume robotic assisted nephro-ureterectomy allows improved perioperative outcomes
- 1 June 2021
- Published by Elsevier in European Urology
- Vol. 79, S1108
High volume robotic assisted nephro-ureterectomy allows improved perioperative outcomes